Meleveetil Damodaran seems to have a knack of setting things right wherever he goes. While his formidable abilities have no doubt played a big role in this, circumstances have also helped him greatly.
India is the fourth largest manufacturer of pharmaceutical products in the world and the 12th largest in value terms. India could emerge as the second largest producer of active pharmaceutical ingredients (API), next to China, within two to five years, overtaking Italy, according to various estimates.
The Indian classical music industry is stuck in a rut, and topmost on everybody's blame list is the record label.
Economic Advisor to the Tata Group Siddhartha Roy tells Business Standard the economy may be slowing down.
There's plenty of room for everybody. With the demand for low-cost accommodation on the rise, a whole host of hospitality firms, both foreign and local, is planning to set up budgets hotels.
An interview with Sebi chief M Damodaran.
The short point: CEOs, it appears, prefer to play it safe until it's too late. There's a study of how managements tend to be lethargic if they command the lion's share of the market, a case in point being Bajaj Auto in the autorickshaws space.
ONGC Videsh (OVL), a wholly owned subsidiary of Oil and Natural Gas Corporation (ONGC), is eyeing more gas fields in Libya.
After decades of selling to the middle class, a clutch of companies is now going after richer customers as well.
Rohm and Haas, one of the largest speciality material manufacturers in the world, plans to invest $100 million (about Rs 410 crore) in India to develop manufacturing and research and development facilities.
According to senior RIL executives, more than half the work has been completed on the pipeline, which will transport gas from the KG basin to the RIL refinery at Jamnagar.
A study by a Swedish University has accused India's Active Pharmaceutical Ingredient (API) manufacturers of causing alarming levels of environmental pollution and threatening the region's flora and fauna.
The under-leveraged nature of corporates will help reduce the impact.
Even as some major global pharmaceutical majors like Novartis say India's patent laws are weak and a hurdle to their investment plans for the country
If a science graduate or a B Pharma degree was the minimum requirement for the job of medical representative some years ago, acute manpower crisis and inability to penetrate rural areas have forced the phramaceutical industry
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
P B Jayakumar caught up Dr Reddy's chairman K Anji Reddy and tried to balance science and religion. And yes, there is also the question of choosing between the son and the son-in-law.
Mumbai-based pharma major Lupin will invest over Rs 200 crore (Rs 2 billion) this year to create additional manufacturing capacities.
The steel-maker will now have to pay 50 basis points more on this tranche of $1 billion with a seven-year tenure.
Better prices and smaller packet sizes help Tata Tea concoct a winning brew.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances